Rune Labs is enrolling patients with multiple sclerosis (MS) in a study that aims to identify neurophysiological biomarkers of the disease, according to a press release from the company. During the study, demyelination, a hallmark symptom of MS, will be measured using a closed loop technology.

“By taking advantage of access to the spinal cord provided during routine clinical procedures, this study will capture precise neurophysiological data and measure myelination using a variety of evoked potentials,” Ro’ee Gilron, the lead neuroscientist at Rune Labs, said in the press release. “Rune’s [artificial intelligence] platform enables us to take raw brain data and convert it into actionable biomarkers of myelination.”

During the study, patients will receive a spinal cord stimulator that will reduce neuropathic pain. Electrophysiological signals from the spinal cord and cortex will also be recorded, which will allow the underlying physiology leading to myelination to be measured.

Continue Reading

Read more about the symptoms of MS

There are currently no biomarkers that can measure the degree of myelination in a patient. Metrics that are used in clinical trials such as the Expanded Disability Status Scale are nonlinear, fluctuate widely, or are stagnant, which makes them imprecise and not always correlating with the activity of lesions. It is therefore difficult to understand how efficient a remyelinating drug is.

“If we’re going to develop effective disease-modifying therapies, and design and run more efficient clinical trials that capture efficacy signals, we’ll need precise, non-invasive biomarkers that measure the degree of myelination and reflect disease pathology,” said Krishnan Chakravarthy, MD, PhD, cofounder of Coastal Research Institute who has partnered with Rune Labs for the study.

This study will allow the development of an MS metric that is sensitive to the degree of myelination and can be used to increase a clinical score, according to the company.


Rune Labs partners with coastal Research Institute to identify biomarkers of multiple sclerosis lesions using AI platform to analyze patient neurophysiological data. News release. Rune Labs; July 14, 2022.